Biotech Mesoblast to be hit with class action over COVID-19 treatment disclosures
Class Actions 2021-04-22 9:25 pm By Cindy Cameronne | Sydney
Please login to bookmark Close

Australian regenerative medicine company Mesoblast faces a shareholder class action over disclosures related to its Remestemcel-L treatment for COVID-19 complications.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au